Model could support the assessment of long-term chronic drug therapies and help clinicians develop more effective treatments for complex diseases
Using artificial intelligence, a team of University at Buffalo researchers has developed a novel system that models the progression of chronic diseases as patients age.
Published in Oct. in the Journal of Pharmacokinetics and Pharmacodynamics, the model assesses metabolic and cardiovascular biomarkers – measurable biological processes such as cholesterol levels, body mass index, glucose and blood pressure – to calculate health status and disease risks across a patient’s lifespan.
The findings are critical due to the increased risk of developing metabolic and cardiovascular diseases with aging, a process that has adverse effects on cellular, psychological and behavioral processes.
“There is an unmet need for scalable approaches that can provide guidance for pharmaceutical care across the lifespan in the presence of aging and chronic co-morbidities,” says lead author Murali Ramanathan, PhD, professor of pharmaceutical sciences in the UB School of Pharmacy and Pharmaceutical Sciences. “This knowledge gap may be potentially bridged by innovative disease progression modeling.”
The model could facilitate the assessment of long-term chronic drug therapies, and help clinicians monitor treatment responses for conditions such as diabetes, high cholesterol and high blood pressure, which become more frequent with age, says Ramanathan.
Additional investigators include first author and UB School of Pharmacy and Pharmaceutical Sciences alumnus Mason McComb, PhD; Rachael Hageman Blair, PhD, associate professor of biostatistics in the UB School of Public Health and Health Professions; and Martin Lysy, PhD, associate professor of statistics and actuarial science at the University of Waterloo.
The research examined data from three case studies within the third National Health and Nutrition Examination Survey (NHANES) that assessed the metabolic and cardiovascular biomarkers of nearly 40,000 people in the United States.
Biomarkers, which also include measurements such as temperature, body weight and height, are used to diagnose, treat and monitor overall health and numerous diseases.
The researchers examined seven metabolic biomarkers: body mass index, waist-to-hip ratio, total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose and glycohemoglobin. The cardiovascular biomarkers examined include systolic and diastolic blood pressure, pulse rate and homocysteine.
By analyzing changes in metabolic and cardiovascular biomarkers, the model “learns” how aging affects these measurements. With machine learning, the system uses a memory of previous biomarker levels to predict future measurements, which ultimately reveal how metabolic and cardiovascular diseases progress over time.
Original Article: AI-powered computer model predicts disease progression during aging
More from: University at Buffalo | University of Waterloo
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Long-term chronic drug therapies
- Rise in Long-term Illnesses Compel Key Players to…
The global pharmaceutical drug delivery market is projected to have a high-paced CAGR of 6.4% during the forecast period. The current valuation of the pharmaceutical drug delivery market is US$ 1.9 ...
- Medical cannabis for chronic pain may help patients on long-term opioid treatment reduce dosages
A new study from New York State and CUNY researchers suggests that receiving medical cannabis for thirty days or more may help patients on long-term opioid treatment to lower their dose over time.
- What it’s like to take the blockbuster drugs Ozempic and Wegovy, from severe side effects to losing 50 pounds
Ten people taking the medications for weight loss, diabetes or other chronic health conditions described a wide variety of experiences.
- Is it safe to take the anti-obesity drug Wegovy long-term? Doctors weigh in
“This supports the belief that obesity is a chronic disease that requires ... for which most patients remain on therapy long term in order to continue to experience the benefits of their medications.” ...
- Significant Improvements: A New, Promising Long-Term Treatment for Eczema
Patients experienced significant improvement in their symptoms, even up to 20 weeks after they had stopped taking the medication. Mount Sinai researchers have reported promising results from a ...
Go deeper with Google Headlines on:
Long-term chronic drug therapies
[google_news title=”” keyword=”long-term chronic drug therapies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Progression of chronic diseases
- Biomarker identification important for future of chronic inflammatory bowel disease treatment: GlobalData
According to GlobalData, the market for the UC is filled with several different treatment options, and the pipeline is relatively strong.
- Gold Nanoparticle Sensors for Detecting Chronic Kidney Disease and Disease Progression
Aim: To study the feasibility of a novel nanomedical method that utilizes breath testing for identifying chronic kidney disease (CKD) and disease progression. Materials & Methods: Exhaled breath ...
- Renal Disease Market 2023 : Top Manufacturers, Key Trends, Progression Status and Business Trends to 2029
The MarketWatch News Department was not involved in the creation of this content. Jan 26, 2023 (The Expresswire) -- Renal Disease Market Size is projected to Reach Multimillion USD by 2029, In ...
- Intensive Blood Pressure Control May Delay Progression in Advanced Chronic Kidney Disease
Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control.
- FDA reviews Empagliflozin's potential for arresting progression of chronic kidney disease
USA: Jardiance (empagliflozin) tablets have received the supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA). Jardiance is being investigated as a ...
Go deeper with Google Headlines on:
Progression of chronic diseases
[google_news title=”” keyword=”progression of chronic diseases” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
